Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
Reneo Pharmaceuticals (NASDAQ: RPHM) will provide a corporate update and engage in one-on-one investor meetings at the virtual Ladenburg Thalmann 2021 Healthcare Conference on July 13-14, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reneo Pharmaceuticals (NASDAQ: RPHM) will provide a corporate update and engage in one-on-one investor meetings at the virtual Ladenburg Thalmann 2021 Healthcare Conference on July 13-14, 2021. The company is focused on developing therapies for rare genetic mitochondrial diseases, notably REN001, which aims to enhance ATP production by modulating key metabolic genes. REN001 has demonstrated potential in improving mitochondrial function and fatty acid oxidation.
Details
News Market Reaction – RPHM
The recorded move for RPHM in the trading session of this news was -1.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.
About Reneo Pharmaceuticals
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
Contacts:
Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.